Alzheimer's treatment in nursing homes: Room for improvement

Journal of the American Medical Directors Association

Volumn 7, Issue 2, 2006, Pages 90-95

  Bright Long, Lory ^a,b  

^a State University of New York ^*  (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Acetylcholinesterase inhibitors (cholinesterase inhibitors); Alzheimer's disease (AD); Long term care; Nursing home

Indexed keywords

ACETAZOLAMIDE; CARBAMAZEPINE; CARBONATE DEHYDRATASE INHIBITOR; CHOLINESTERASE INHIBITOR; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DONEPEZIL; ERYTHROMYCIN; GALANTAMINE; HYDROCHLOROTHIAZIDE; KETOCONAZOLE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PAROXETINE; PHENOBARBITAL; PLACEBO; RIVASTIGMINE; TACRINE;

ADMINISTRATIVE PERSONNEL; ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COMMUNITY CARE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG COST; DRUG POTENTIATION; DRUG SAFETY; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HUMAN; LONG TERM CARE; MANAGED CARE; MEDICAL DECISION MAKING; MENTAL DISEASE; NURSING HOME; PHYSICAL ACTIVITY; PHYSICIAN; REVIEW;

EID: 32444443764     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2005.09.010     Document Type: Article

References (54)

1. G.W. Small P.V. Rabins P.P. Barry et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society JAMA 278 1997 1363-1371
2. E.D. Eaker R.A. Vierkant S.F. Mickel Predictors of nursing home admission and/or death in incident Alzheimer's disease and other dementia cases compared to controls: A population-based study J Clin Epidemiol 55 2002 462-468
3. L.E. Hebert P.A. Scherr J.L. Bienias et al. Alzheimer disease in the US population: Prevalence estimates using the 2000 census Arch Neurol 60 2003 1119-1122
4. Krauss NA, Altman BM. Research findings no. 5: Characteristics of nursing home residents-1996. January 2005. Agency for Healthcare Research and Quality. Available at: http://www.meps.ahrq.gov/papers/ rf5_99-0006/rf5.htm. Accessed January 18, 2005.
5. D. Galasko An integrated approach to the management of Alzheimer's disease: Assessing cognition, function and behaviour Eur J Neurol 5 suppl 4 1998 S9-S17
6. D.W. Gilley R.S. Wilson D.A. Bennett et al. Predictors of behavioral disturbance in Alzheimer's disease J Gerontol 46 1991 P362-P371
7. T.L. Hopper "They're just going to get worse anyway": perspectives on rehabilitation for nursing home residents with dementia J Commun Disord 36 2003 345-359
8. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 4th ed 1994 American Psychiatric Press Washington, DC
9. J.N. Morris B.E. Fries D.R. Mehr et al. MDS Cognitive Performance Scale J Gerontol 49 1994 M174-M182
10. S.L. Hartmaier P.D. Sloane H.A. Guess et al. Validation of the Minimum Data Set Cognitive Performance Scale: Agreement with the Mini-Mental State Examination J Gerontol A Biol Sci Med Sci 50 1995 M128-M133
11. S.L. Hartmaier P.D. Sloane H.A. Guess et al. The MDS cognition scale: A valid instrument for identifying and staging nursing home residents with dementia using the Minimum Data Set J Am Geriatr Soc 42 1994 1173-1179
12. American Medical Directors Association. Dementia: Clinical Practice Guideline 1998. Columbia, MD: American Medical Directors Association, 1998. Available at: www.amda.com. Accessed August 16, 2005.
13. Aricept [package insert]. Teaneck, NJ: Eisai Inc, 2004. Available at: www.eisai.com or www.aricept.com. Accessed August 16, 2005.
14. Reminyl [package insert]. Titusville, NJ: Janssen Pharmaceutica, 2003. Available at: Www.janssen.com, www. Reminyl.com, or www. Razadyne.com. Accessed August 16, 2005.
15. Exelon [package insert]. East Hanover, NJ: Novartis, 2004. Available at: www.novartis.com or www.exelon.com. Accessed August 16, 2005.
16. Cognex [package insert]. Roswell, GA: First Horizon Pharmaceutical, 2000. Available at: www.horizonpharm.com. Accessed August 16, 2005
17. J.L. Cummings J.C. Frank D. Cherry et al. Guidelines for managing Alzheimer's disease: Part II. Treatment Am Fam Physician 65 2002 2525-2534
18. Namenda [package insert]. St Louis, MO: Forest Laboratories Inc, 2003. Available at: www.forestpharm.com or www.namenda.com. Accessed August 16, 2005.
19. R.T. Bartus R.L. Dean III B. Beer et al. The cholinergic hypothesis of geriatric memory dysfunction Science 217 1982 408-414
20. J.P. Blass Pathophysiology of the Alzheimer's syndrome Neurology 43 suppl 4 1993 S25-S38
21. P.T. Francis A.M. Palmer M. Snape et al. The cholinergic hypothesis of Alzheimer's disease: A review of progress J Neurol Neurosurg Psychiatry 66 1999 137-147
22. P.T. Francis Glutamatergic systems in Alzheimer's disease Int J Geriatr Psychiatry 18 suppl 1 2003 S15-S21
23. J. Corey-Bloom R. Anand J. Veach et al. 1998 randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease Int J Geriatr Psychopharmacol 1 1998 55-65
24. K. Rockwood J. Mintzer L. Truyen et al. Effects of a flexible galantamine dose in Alzheimer's disease: A randomised, controlled trial J Neurol Neurosurg Psychiatry 71 2001 589-595
25. S.L. Rogers M.R. Farlow R.S. Doody et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease Neurology 50 1998 136-145
26. S.L. Rogers R.S. Doody R.C. Mohs et al. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study Arch Intern Med 158 1998 1021-1031
27. M. Rosler R. Anand A. Cicin-Sain et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial [published erratum appears in: BMJ 2001;322:1456] BMJ 318 1999 633-638
28. P.N. Tariot P.R. Solomon J.C. Morris et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD Neurology 54 2000 2269-2276
29. G.K. Wilcock S. Lilienfeld E. Gaens et al. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial. [published erratum appears in BMJ 2001;322:405] BMJ 321 2000 1445-1449
30. B. Winblad K. Engedal H. Soininen et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD Neurology 57 2001 489-495
31. R.C. Mohs R.S. Doody J.C. Morris et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients [published erratum appears in Neurology 2001;57:1942] Neurology 57 2001 481-488
32. R.S. Doody D.S. Geldmacher B. Gordon et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease Arch Neurol 58 2001 427-433
33. M. Farlow R. Anand J. Messina Jr et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease Eur Neurol 44 2000 236-241
34. M.A. Raskind E.R. Peskind T. Wessel et al. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension Neurology 54 2000 2261-2268
35. B. Winblad K. Engedal H. Soininen et al. Long-term efficacy of donepezil in patients with mild to moderate Alzheimer's disease: Results from a one-year placebo-controlled study and two-year follow-up study [abstract] Int Psychogeriatr 15 suppl 2 2003 293-294
36. H. Feldman S. Gauthier J. Hecker et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease [published erratum appears in Neurology 2001;57:2153] Neurology 57 2001 613-620
37. B. Reisberg R. Doody A. Stoffler et al. Memantine in moderate-to-severe Alzheimer's disease N Engl J Med 348 2003 1333-1341
38. P.N. Tariot M.R. Farlow G.T. Grossberg et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial JAMA 291 2004 317-324
39. C. Pedone K.L. Lapane V. Mor et al. Donepezil use in US nursing homes Aging Clin Exp Res 16 2004 60-67
40. P.N. Tariot J.L. Cummings I.R. Katz et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting J Am Geriatr Soc 49 2001 1590-1599
41. S.N. Shah D. Keohane B.D. Strunk et al. Retrospective analysis of characteristics in long-term care residents with Alzheimer's disease continuing versus discontinuing donepezil treatment [abstract] J Am Geriatr Soc 52 suppl 2004 S49
42. B. Winblad N. Poritis Memantine in severe dementia: Results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine) Int J Geriatr Psychiatry 14 1999 135-146
43. J.A. O'Brien J.J. Caro Alzheimer's disease and other dementia in nursing homes: Levels of management and cost Int Psychogeriatr 13 2001 347-358
44. Consumer Price Index Inflation Calculator. US Bureau of Labor Statistics Web site. Available at: http://data.bls.gov/cgi-bin/cpicalc.pl. Accessed May 20, 2005.
45. L. Kleinman J. Schmier M. Rothman et al. Time and costs of managing specific disruptive behaviors in long-term care facilities: A descriptive study Consult Pharm 17 2002 497-507
46. S. Gauthier H. Feldman J. Hecker et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease Int Psychogeriatr 14 2002 389-404
47. S. Gauthier H. Feldman J. Hecker et al. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease Curr Med Res Opin 18 2002 347-354
48. C. Holmes D. Wilkinson C. Dean et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease Neurology 63 2004 214-219
49. M. Rosler W. Retz P. Retz-Junginger et al. Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease Behav Neurol 11 1998 211-216
50. P. Khang N. Weintraub R.T. Espinoza The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: Are the data relevant and available? J Am Med Dir Assoc 5 2004 249-255
51. S.B. Dybicz S.N. Shah W.G. Erwin et al. Patterns of use of cholinesterase inhibitors in the nursing home environment [abstract] Neurology 62 suppl 5 2004 A214
52. S.T. Bogardus Jr When should one stop cholinesterase inhibitors in patients with Alzheimer's disease? J Psychiatry Neurosci 26 2001 425
53. P. Johannsen M. Barcikowska P. et al. Dautzenberg Donepezil-treated Alzheimer's disease patients with apparent initial cognitive decline demonstrate significant benefits when therapy is continued: Results from a randomized, placebo-controlled trial [abstract] Int Psychogeriatr 15 suppl 2 2003 106-107
54. R.S. Doody J.K. Dunn C.M. Clark et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease Dement Geriatr Cogn Disord 12 2001 295-300